Covid-19 Tools Accelerator Faces $35-Billion Funding Gap: WHO Director-General

covid-19 cancer
Tedros Adhanom Ghebreyesus,
Director-General of the World Health Organization

World Health Organisation (WHO) Director-General Tedros Adhanom Ghebreyesus speaking at a news briefing in Geneva said, “No disease in history has seen such rapid development in research. The world’s ambition to develop these tools as fast as possible must be matched by its ambition to ensure as many people as possible have access to them. The ACT Accelerator will not be able to deliver on its goals without a significant increase in funding; it still faces a funding gap of 35 billion US dollars.”

An ACT Accelerator high-level event at the United Nations General Assembly will take place on 30 September. Since the beginning of the pandemic, accelerating the development of and equitable access to vaccines, diagnostics and therapeutics for Covid-19 has been a priority for WHO.

His statement comes as more daily recoveries from the novel coronavirus have improved consistently in terms of absolute numbers even as new cases are rising in an unstoppable fashion in India. Single-day spike of 95,735 new Covid-19 cases & 1,172 deaths reported in India, on Thursday. The total case tally stands at 44, 65,864 including 919018 active cases, 3471784 cured/discharged/migrated & 75062 deaths.

‘Already, we have made remarkable progress. In January, within two weeks of the first cases being reported to WHO, we published the first protocol for PCR testing for the new coronavirus. Since then, millions of tests have been produced, and already rapid tests are now starting to be used. In February, WHO brought together hundreds of scientists and researchers to identify research priorities.  In March, we launched the Solidarity Trial, to find answers fast about which therapeutics are the most effective’; Tedros told a news briefing in Geneva.

‘One therapeutic – dexamethasone – has already been proven effective for patients with the severe and critical disease, and around 180 vaccines are now in development, including 35 that are in human trials. No disease in history has seen such rapid development in research. Ambition is to develop these tools as fast as possible and it must be matched by its ambition to ensure as many people as possible have access to them’, he added.

“The ACT Accelerator still faces a funding gap of 35 billion US dollars and it will not be able to deliver on its goals without a significant increase in funding”, he said, calling for the rapid scaling up of the clinical trials as well as the manufacturing, licensing and regulation capacity.

“WHO launched the Access to Covid-19 Tools Accelerator, to catalyse the development of and equitable access to vaccines, diagnostics and therapeutics. The 2.7 billion US dollars it has received to date has been generous and has enabled the robust start-up phase. But this is less than 10 percent of the overall needs”, he added.

“Between now and the end of the year we have a limited window of opportunity to scale-up the ACT Accelerator and fully enable the equitable allocation framework”, Tedros said, adding that the world’s ambition to develop these tools as fast as possible

Leave a Reply

Your email address will not be published. Required fields are marked *

kuwin

iplwin

my 11 circle

betway

jeetbuzz

satta king 786

betvisa

winbuzz

dafabet

rummy nabob 777

rummy deity

yono rummy

shbet

kubet

betvisa

winbuzz

six6s

babu88

marvelbet

krikya

winbuzz

daman game

mostplay login

4rabet login

leonbet login

pin up aviator

mostbet login

rummy wealth

Fastwin App

×